Foundayo Pros and Cons: An Honest Verdict for UK Patients

The Medicines and Healthcare products Regulatory Agency (MHRA) recently approved Foundayo (orforglipron), a GLP-1 weight loss pill. It's a promising option for people who want weight management treatments but are struggling with needle phobia or frustrated by the strict fasting rules of other weight-loss pills.

However, making a good decision about your health requires weighing the real-world advantages against the drawbacks. Patients considering the pill should understand the benefits Foundayo offers and the potential shortcomings that might make it unsuitable for some people.

This blog breaks down the key Foundayo pros and cons to help you decide if starting or switching to this daily pill is right for your weight loss journey.

Key Takeaways

• Foundayo (orforglipron) is a once-daily GLP-1 weight loss tablet approved in the UK in August 2026.
• Unlike some other oral GLP-1 treatments, Foundayo can be taken with or without food, making it easier to fit into your daily routine.
• Clinical trials show that orforglipron can help patients lose around 11–15% of their body weight, although results vary.
• Common drawbacks of Foundayo include weakening oral contraceptives, slightly lower results for some people, and the need to remember a daily dose.
• Curely can help you determine whether Foundayo is the right treatment for you.

What Is Foundayo?

Foundayo is Eli Lilly's brand name for orforglipron, a once-daily tablet for chronic weight management that was approved for use in the UK in August 2026. Orforglipron is a GLP-1 receptor agonist, similar to weight loss injections on the market, which work by regulating appetite and making you fuller for longer. Foundayo also helps regulate blood sugar.

Peptide-based GLP-1 medications (such as Wegovy and Mounjaro) are large protein chains that stomach acid breaks down quickly. Orforglipron, on the other hand, is a small molecule. Its chemical structure makes it stable in the digestive system, allowing it to be made into a pill that can be taken without food or water restrictions.

The Pros of Foundayo

As an oral GLP-1 weight-loss medication, orforglipron has several advantages over weight-loss injections and other pills. They include:

No Needles

Some patients who could benefit from GLP-1 medications may be uncomfortable with injections. Foundayo solves that because it's a daily pill, making it easier for people who need this treatment but can't get injections.

It also means patients don't need refrigeration or weight loss accessories like sharps disposal bins and travel cases.

No Food or Water Restrictions

Not all weight loss pills have the same administration rules. For example, patients taking the Wegovy pill (semaglutide) must take it on an empty stomach first thing in the morning before eating or drinking anything, including other medications.

You must swallow the pill whole with no more than 120ml of plain water, then wait at least 30 minutes before eating or drinking anything. Patients must follow these rules for the Wegovy pill because it's a peptide, which makes it difficult for the stomach to absorb without breaking it down.

Foundayo is a small molecule with a more stable structure, meaning you can take it at any time of day, with or without food or water. It's more convenient and easier to fit into your schedule.

Proven Weight Loss Results

According to the ATTAIN-1 Phase 3 clinical trials, adults with obesity or overweight symptoms taking the highest dose of orforglipron for 72 weeks alongside lifestyle support lost an average of 12.4 kg (12.4% of body weight).

Metabolic Health Improvements

Foundayo regulates blood sugar, a major benefit for people with type 2 diabetes. As you lose weight, the medication stimulates glucose-dependent insulin secretion from the pancreas while preventing the liver from dumping excess sugar into the bloodstream.

People taking Foundayo may also notice reduced visceral and subcutaneous fat, which means a smaller waist measurement and lower total cholesterol.

Supports Your Liver and Kidney Health

People with mild-to-moderate kidney or liver conditions often need strict monitoring or dosage tweaks to avoid stressing their organs when taking medications. One of the standout benefits of orforglipron is that it breaks down predictably in the body without putting extra strain on your system.

Cons of Foundayo

[Photo by Juleta Martirosyan on Canva].

Orforglipron has some disadvantages which may make it unsuitable for some patients. They include:

Slightly Lower Efficacy

Foundayo achieved an average weight loss of ~11% to 15% at the highest doses, which is impressive for a daily pill. However, injectable medications such as Mounjaro and Wegovy average ~20%+ body weight loss. Some oral semaglutide doses also show higher weight-loss results, as covered in our guide on GLP-1 tablets vs injections

However, it's important to note that individual results can vary depending on factors such as starting weight and how well you respond to the medication. Speak to Curely if you're concerned about your weight loss progress on Foundayo.

Common GI Issues

Common Foundayo side effects include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Indigestion
• Stomach pain

These side effects are common among GLP-1 treatments. They're often more noticeable when you start taking the medication and during Foundayo dose increases, but should improve as your body adjusts to the medication.

Seek immediate medical help if you notice serious complications such as severe stomach pain that doesn't go away, persistent vomiting or diarrhoea, or serious allergic reactions such as difficulty breathing.

Daily Dosing

Foundayo is a daily tablet, so you need to stick to this schedule. Some people struggle to remember a daily pill, and missing doses regularly can reduce Foundayo's effectiveness. Setting a reminder can help you stick to the schedule.

Weakening Oral Contraception

According to the Summary of Product Characteristics (SmPC), orforglipron may reduce the efficacy of birth control pills. Patients should switch to a non-oral contraceptive method or add a barrier (such as condoms) when starting treatment and during dose adjustments.

Serious Risks and Warnings of Foundayo

[Photo by Alex P on Canva].

Every prescription drug comes with a set of important safety parameters, and Foundayo is no exception. These guidelines aren't necessarily reasons to avoid orforglipron, but important factors that you should evaluate when deciding if it's the right fit for your weight loss needs. They include:

Pancreatitis

While uncommon, inflammation of the pancreas (pancreatitis) is a risk with GLP-1 medications such as Foundayo. A key warning sign is severe abdominal pain that feels sharp or deep and may spread to your back, often accompanied by persistent nausea.

Stop taking your medication and seek immediate medical attention if you experience these severe symptoms.

Our clinical team always reviews your medical history, including any past issues with your pancreas, to ensure the treatment is safe for you.

Gallbladder Disease

Gallbladder problems, such as gallstones or inflammation, can occur while taking Foundayo. This risk is mainly connected to the rapid weight loss that often occurs on GLP-1 treatments.

Watch for sudden pain in your upper right stomach or yellowing of your skin or eyes, especially during the first few weeks of treatment or after a dose increase.

Kidney Problems

Foundayo doesn't directly affect kidney tissue, but its most common side effects, such as vomiting or diarrhoea, can lead to severe dehydration and eventually, acute kidney injury.

People with established kidney disease should speak to a physician before taking Foundayo. Also, seek medical advice if common symptoms such as vomiting and diarrhoea don't improve after some time.

Always inform your doctor about any over-the-counter medicines or prescriptions you take, as some can interact with orforglipron, putting more strain on your kidneys.

Low Blood Sugar (Hypoglycemia)

Foundayo stimulates insulin production when your blood glucose is high. However, if you take it alongside other medicines for diabetes, it can increase the risk of hypoglycemia. Symptoms include shakiness, sweating, confusion, and dizziness.

Always speak to your doctor if you're on other medications before taking orforglipron. They'll start you on a low dose and make adjustments as you progress in weight loss.

Thyroid C-Cell Tumors

Animal studies on GLP-1 medications have shown a potential link to thyroid cancer. For this reason, Foundayo is strictly contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Curely Online Pharmacy: The Best Choice for Weight Loss Treatments

At Curely, we make your weight loss journey easy with legitimately sourced medications and transparent pricing.

We offer Foundayo to eligible patients in the UK after a quick online consultation that checks your medical history and starting weight. Once approved, we'll ship the medication in unmarked packaging to your selected address for free.

And if Foundayo isn't the right choice, Curely offers a variety of treatments, including pills and injections.

Our pricing is transparent, and you stay in control throughout treatment. No cancellation fees, and you have the freedom to adjust or pause your subscription whenever you want.

Start your weight loss journey with Curely today.

Effective weight management

Weight Loss Medication

Easy access to treatment with trusted pharmacist support.

Begin Consultation

FAQs

What Are the Most Common Foundayo Side Effects?

Orforglipron causes gastrointestinal side effects such as nausea, vomiting, diarrhoea, constipation, indigestion and abdominal pain. These symptoms are common for GLP-1 medications, and they usually improve as your body adjusts to the medication. Speak to a doctor immediately if they don't improve after some time, or if you notice symptoms such as persistent abdominal pain or a severe allergic reaction.

Is Foundayo Available in the UK?

The MHRA authorised Foundayo on August 10, 2026 and Eli Lilly launched it on August 24, 2026, through private prescription only. The National Health Service (NHS) doesn't fund the pill because the National Institute for Health and Care Excellence (NICE) hasn't completed its appraisal. However, you can get Foundayo conveniently through Curely's weight loss service.

Do Weight Loss Pills Work?

Many approved weight loss pills in the UK help patients lose excess weight and manage blood sugar. Foundayo, for example, showed an average weight loss of 11.2% at the highest dose studied over 72 weeks, compared with 2.1% on placebo. Older pills such as orlistat produce smaller average losses because they work differently. Reach out to Curely if you're concerned about weight loss results, and we'll help you find the best solution.

Final Thoughts

Foundayo offers the benefits of a GLP-1 weight-loss treatment without the needles. It also has no food or water restrictions, making it more convenient for daily dosing.

Like all other medications, it has some shortcomings that may make it unsuitable for some patients. For example, the weight loss results may be too low for people who need to lose a lot of weight quickly.

This doesn’t mean Foundayo is a bad choice for everyone, as results depend on how you respond to the medication.

Curely can help you find the best treatment based on your goals and medical history. Complete our online consultation today to start your weight loss journey.

References

• Espinosa De Ycaza AE, Brito JP, McCoy RG, Shao H, Singh Ospina N. Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review. Thyroid®. Published online March 26, 2024.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
• Lilly. ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health | Eli Lilly and Company. Eli Lilly and Company. 2025.
• Lilly E. Lilly’s oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine | Eli Lilly and Company. Eli Lilly and Company. 2024.
• Medicines and Healthcare products Regulatory Agency. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. GOV.UK. August 10, 2026.
• Wharton S, Ildiko Lingvay, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393(11):1077-1087.